Real-World Treatment Persistence with Biologic Disease-Modifying Antirheumatic Drugs Among German Patients with Psoriatic Arthritis—A Retrospective Database Study (2024)

Sewerin, P., Borchert, K., Meise, D., Schneider, M., & Mahlich, J. (2021). Real-World Treatment Persistence with Biologic Disease-Modifying Antirheumatic Drugs Among German Patients with Psoriatic Arthritis—A Retrospective Database Study. Rheumatology and Therapy, 8(1), 483-497. https://doi.org/10.1007/s40744-021-00286-z

Sewerin, Philipp ; Borchert, Kathrin ; Meise, Dominic et al. / Real-World Treatment Persistence with Biologic Disease-Modifying Antirheumatic Drugs Among German Patients with Psoriatic Arthritis—A Retrospective Database Study. in: Rheumatology and Therapy. 2021 ; Band 8, Nr. 1. S. 483-497.

@article{957151e720324be1aee3e00cd52da2c9,

title = "Real-World Treatment Persistence with Biologic Disease-Modifying Antirheumatic Drugs Among German Patients with Psoriatic Arthritis—A Retrospective Database Study",

abstract = "Introduction: To investigate drug survival for biologic disease-modifying antirheumatic drugs (bDMARDs) in a real-world cohort of German adult biologic-na{\"i}ve patients with psoriatic arthritis (PsA). Methods: Claims data for patients with a diagnosis of PsA, a bDMARD claims record (index date) between 1 January 2014 and 31 December 2017, and no bDMARD prescription for 365days before the index date were retrospectively analyzed. The primary outcomes were the overall and individual bDMARD persistence rates over 12months. Nonpersistence was defined as a treatment gap exceeding the days of supply plus 60days or switching to a bDMARD other than the index therapy. Sensitivity analysis was performed, wherein the treatment gap was found to vary depending on the bDMARD regimen. Kaplan–Meier curves were plotted to determine persistence; the log-rank test was used to evaluate differences in the persistence rate. Factors associated with treatment discontinuation were evaluated using Cox regression analysis. Results: Among 10,954 patients with a PsA diagnosis, 348 were eligible. The overall bDMARD persistence rate was 57.5%; individual bDMARD persistence rates were 81.3% for ustekinumab, 66.7% for infliximab, and 60.0% for golimumab. The mean (SD) overall persistence with bDMARDs was 289 (103) days; the mean persistence was 334 (72) days for ustekinumab, 309 (82) days for golimumab, and 305 (92) days for infliximab. The main reasons for nonpersistence were switching to another bDMARD (15.8%) and treatment discontinuation (26.7%). Male gender was significantly associated with a lower risk of treatment discontinuation (hazard ratio 0.54, 95% confidence interval 0.39–0.77; P < 0.001). The sensitivity analysis yielded similar results. Conclusion: The one-year persistence rate for bDMARDs in German PsA patients is modest, although the persistence rate depends on the bDMARD considered.",

keywords = "Biologic disease-modifying antirheumatic drugs, Germany, Persistence, Psoriatic arthritis",

author = "Philipp Sewerin and Kathrin Borchert and Dominic Meise and Matthias Schneider and J{\"o}rg Mahlich",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = mar,

doi = "10.1007/s40744-021-00286-z",

language = "English",

volume = "8",

pages = "483--497",

journal = "Rheumatology and Therapy",

issn = "2198-6576",

publisher = "Springer",

number = "1",

}

Sewerin, P, Borchert, K, Meise, D, Schneider, M & Mahlich, J 2021, 'Real-World Treatment Persistence with Biologic Disease-Modifying Antirheumatic Drugs Among German Patients with Psoriatic Arthritis—A Retrospective Database Study', Rheumatology and Therapy, Jg. 8, Nr. 1, S. 483-497. https://doi.org/10.1007/s40744-021-00286-z

Real-World Treatment Persistence with Biologic Disease-Modifying Antirheumatic Drugs Among German Patients with Psoriatic Arthritis—A Retrospective Database Study. / Sewerin, Philipp; Borchert, Kathrin; Meise, Dominic et al.

in: Rheumatology and Therapy, Band 8, Nr. 1, 03.2021, S. 483-497.

Veröffentlichungen: Beitrag in Fachzeitschrift › Artikel › Peer Reviewed

TY - JOUR

T1 - Real-World Treatment Persistence with Biologic Disease-Modifying Antirheumatic Drugs Among German Patients with Psoriatic Arthritis—A Retrospective Database Study

AU - Sewerin, Philipp

AU - Borchert, Kathrin

AU - Meise, Dominic

AU - Schneider, Matthias

AU - Mahlich, Jörg

N1 - Publisher Copyright:© 2021, The Author(s).

PY - 2021/3

Y1 - 2021/3

N2 - Introduction: To investigate drug survival for biologic disease-modifying antirheumatic drugs (bDMARDs) in a real-world cohort of German adult biologic-naïve patients with psoriatic arthritis (PsA). Methods: Claims data for patients with a diagnosis of PsA, a bDMARD claims record (index date) between 1 January 2014 and 31 December 2017, and no bDMARD prescription for 365days before the index date were retrospectively analyzed. The primary outcomes were the overall and individual bDMARD persistence rates over 12months. Nonpersistence was defined as a treatment gap exceeding the days of supply plus 60days or switching to a bDMARD other than the index therapy. Sensitivity analysis was performed, wherein the treatment gap was found to vary depending on the bDMARD regimen. Kaplan–Meier curves were plotted to determine persistence; the log-rank test was used to evaluate differences in the persistence rate. Factors associated with treatment discontinuation were evaluated using Cox regression analysis. Results: Among 10,954 patients with a PsA diagnosis, 348 were eligible. The overall bDMARD persistence rate was 57.5%; individual bDMARD persistence rates were 81.3% for ustekinumab, 66.7% for infliximab, and 60.0% for golimumab. The mean (SD) overall persistence with bDMARDs was 289 (103) days; the mean persistence was 334 (72) days for ustekinumab, 309 (82) days for golimumab, and 305 (92) days for infliximab. The main reasons for nonpersistence were switching to another bDMARD (15.8%) and treatment discontinuation (26.7%). Male gender was significantly associated with a lower risk of treatment discontinuation (hazard ratio 0.54, 95% confidence interval 0.39–0.77; P < 0.001). The sensitivity analysis yielded similar results. Conclusion: The one-year persistence rate for bDMARDs in German PsA patients is modest, although the persistence rate depends on the bDMARD considered.

AB - Introduction: To investigate drug survival for biologic disease-modifying antirheumatic drugs (bDMARDs) in a real-world cohort of German adult biologic-naïve patients with psoriatic arthritis (PsA). Methods: Claims data for patients with a diagnosis of PsA, a bDMARD claims record (index date) between 1 January 2014 and 31 December 2017, and no bDMARD prescription for 365days before the index date were retrospectively analyzed. The primary outcomes were the overall and individual bDMARD persistence rates over 12months. Nonpersistence was defined as a treatment gap exceeding the days of supply plus 60days or switching to a bDMARD other than the index therapy. Sensitivity analysis was performed, wherein the treatment gap was found to vary depending on the bDMARD regimen. Kaplan–Meier curves were plotted to determine persistence; the log-rank test was used to evaluate differences in the persistence rate. Factors associated with treatment discontinuation were evaluated using Cox regression analysis. Results: Among 10,954 patients with a PsA diagnosis, 348 were eligible. The overall bDMARD persistence rate was 57.5%; individual bDMARD persistence rates were 81.3% for ustekinumab, 66.7% for infliximab, and 60.0% for golimumab. The mean (SD) overall persistence with bDMARDs was 289 (103) days; the mean persistence was 334 (72) days for ustekinumab, 309 (82) days for golimumab, and 305 (92) days for infliximab. The main reasons for nonpersistence were switching to another bDMARD (15.8%) and treatment discontinuation (26.7%). Male gender was significantly associated with a lower risk of treatment discontinuation (hazard ratio 0.54, 95% confidence interval 0.39–0.77; P < 0.001). The sensitivity analysis yielded similar results. Conclusion: The one-year persistence rate for bDMARDs in German PsA patients is modest, although the persistence rate depends on the bDMARD considered.

KW - Biologic disease-modifying antirheumatic drugs

KW - Germany

KW - Persistence

KW - Psoriatic arthritis

UR - http://www.scopus.com/inward/record.url?scp=85108387036&partnerID=8YFLogxK

U2 - 10.1007/s40744-021-00286-z

DO - 10.1007/s40744-021-00286-z

M3 - Article

AN - SCOPUS:85108387036

VL - 8

SP - 483

EP - 497

JO - Rheumatology and Therapy

JF - Rheumatology and Therapy

SN - 2198-6576

IS - 1

ER -

Sewerin P, Borchert K, Meise D, Schneider M, Mahlich J. Real-World Treatment Persistence with Biologic Disease-Modifying Antirheumatic Drugs Among German Patients with Psoriatic Arthritis—A Retrospective Database Study. Rheumatology and Therapy. 2021 Mär;8(1):483-497. doi: 10.1007/s40744-021-00286-z